Proposal for the use of progression-free survival in unblinded randomized trials.
about
Defining a standard set of patient-centred outcomes for lung cancer.Exact and Asymptotic Weighted Logrank Tests for Interval Censored Data: The interval R package.Missing data in biologic oncology products.Weighted logrank tests for interval censored data when assessment times depend on treatment.The design of phase II clinical trials testing cancer therapeutics: consensus recommendations from the clinical trial design task force of the national cancer institute investigational drug steering committee.Randomized phase II trial of fulvestrant alone or in combination with bortezomib in hormone receptor-positive metastatic breast cancer resistant to aromatase inhibitors: a New York Cancer Consortium trialFuture directions in the treatment of neuroendocrine tumors: consensus report of the National Cancer Institute Neuroendocrine Tumor clinical trials planning meeting.CYP2D6 genotype and tamoxifen response for breast cancer: a systematic review and meta-analysis.Progression-free survival as a primary endpoint in clinical trials of metastatic colorectal cancer.Blinded independent central review of the progression-free survival endpointIn the end what matters most? A review of clinical endpoints in advanced breast cancer.Multitrial Evaluation of Progression-Free Survival as a Surrogate End Point for Overall Survival in First-Line Extensive-Stage Small-Cell Lung Cancer.Ovarian cancer clinical trial endpoints: Society of Gynecologic Oncology white paper.Design Issues in Randomized Clinical Trials of Maintenance Therapies.Blinded independent central review of progression-free survival in phase III clinical trials: important design element or unnecessary expense?Randomized phase II designs.Issues in using progression-free survival when evaluating oncology productsA phase-II trial of dose-dense chemotherapy in patients with disseminated thymoma: report of a Japan Clinical Oncology Group trial (JCOG 9605).Maintenance therapy in nonsmall-cell lung cancer: a new treatment paradigm.Assessing oncologic benefit in clinical trials of immunotherapy agents.Clinical trial end points for high-grade glioma: the evolving landscape.Evaluating surrogacy metrics and investigating approval decisions of progression-free survival (PFS) in metastatic renal cell cancer: a systematic review.Impact of disease progression date determination on progression-free survival estimates in advanced lung cancer.Bevacizumab alone or in combination with TRC105 for patients with refractory metastatic renal cell cancer.Measurement error in the timing of events: effect on survival analyses in randomized clinical trials.Interpreting clinical trial data in multiple myeloma: translating findings to the real-world settingSystematic bias between blinded independent central review and local assessment: literature review and analyses of 76 phase III randomised controlled trials in 45 688 patients with advanced solid tumour
P2860
Q30276400-DC6F5070-1C2D-440F-9DAE-B118E2EBD0C4Q30857508-823FAC90-04A8-4597-B74E-C693FF5EB3C1Q33534317-5996C908-F5D5-4044-B395-834BDF80632EQ33643602-FF3B85AF-CE53-4515-AD4E-3879FDAE1E11Q33732581-63FAFB10-A6F8-4A68-91A0-31694B74CE90Q33915071-4E21CC4F-8339-43B2-89D9-BA0063D903FEQ34743520-2383D734-685F-4969-B650-CDE17785921EQ35009604-F50F3983-1C9D-45E9-882C-404771282D8AQ35223631-F02FA5B9-DF8B-40A4-AF49-DF68A6CA0AC7Q35584061-9F9DC714-C949-43C2-9530-ECC88B55511AQ35584322-1BC081CF-3FBA-4620-9D0E-970D07F528F6Q35825822-0F56A6B0-EF9E-426C-8250-41215F845E33Q36433053-0EC41631-0B8A-42AE-83AE-1A854351206CQ36848078-50D6E548-C8D2-432E-A31C-279420F3D93DQ37126131-34A581A0-CCA7-43B2-B2E7-7A3627C648E6Q37173942-042D319E-CE18-40A9-A4E4-C0B5C878A451Q37231532-468653A0-7D51-4DE1-8990-771CC1616AF2Q37424044-8A2B6BF8-9FF0-49F8-91DB-495933510BACQ37573653-11D9C627-1AFF-48C7-A436-F7B5A62926F6Q37710860-1527E71E-95CF-490D-9B38-901BE17DD51DQ37839482-3C0E75DD-4947-41C8-9EDF-BFE41D338C9EQ38233353-EBE6D4F1-E229-43E8-A5FF-E24ABD4D6BBBQ41962742-E08F0617-A333-402F-89EA-74A7E224BC7AQ46290452-012FFE4C-6E7E-4DA3-B269-8307E292780CQ46307472-6BF21A93-12A3-4886-8D86-3A17079242F8Q58560605-C83CAFC8-5AFE-427C-AFC6-FD9E26316200Q58753938-418EFBA9-A0D2-48E4-81E7-7951E3C660AB
P2860
Proposal for the use of progression-free survival in unblinded randomized trials.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Proposal for the use of progression-free survival in unblinded randomized trials.
@en
type
label
Proposal for the use of progression-free survival in unblinded randomized trials.
@en
prefLabel
Proposal for the use of progression-free survival in unblinded randomized trials.
@en
P2093
P356
P1476
Proposal for the use of progression-free survival in unblinded randomized trials.
@en
P2093
Edward L Korn
Jo Anne Zujewski
Robert Gray
Sally Hunsberger
Scott Saxman
P304
P356
10.1200/JCO.2006.09.6198
P407
P577
2007-05-01T00:00:00Z